Phase 3 N=20 Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
Major Depressive Disorder
Primary: Mood Symptoms Ratings — 33.0; 33.1 CDRS-R score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=151 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Hyperphosphatemia · End-Stage Renal Disease
Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001
Phase 3 N=234 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Disease Progression or Death — 29.7; 34.7 percentage of participants — p=0.254
Phase 3 N=704 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Melanoma
Primary: Overall Survival (OS) — 26.0; 17.8 Months
Phase 3 N=17 Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
Peripheral Artery Disease · Hypertension
Primary: Peak Walking Time (PWT) — 110.4; -19.4 seconds — p=0.039
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 3 N=157 The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
Phase 3 N=54 Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
Epilepsies, Partial
Primary: Number of Participants With Adverse Events (AE). — 14; 13; 11; 9 Participants
Phase 3 N=1,359 Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest
Out-of-hospital Cardiac Arrest
Primary: Number Alive at Hospital Discharge — 187; 183; 62; 76 participants
Phase 3 N=565 Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
Infection; Diabetic Foot
Primary: Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV) — 93.6; 97.3 Percentage of participants
Phase 3 N=120 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 27.3; 15.7; 444.6; 197.0 Titer
Phase 3 N=1,314 LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) as Assessed by Central Independent Review — 3.4; 2.7 months — p=0.0019
Phase 3 N=1,114 Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Carcinoma, Hepatocellular
Primary: Recurrence Free Survival (RFS) by Independent Assessment — 1014; 1026 Days — p==0.258329
Phase 3 N=4,758 Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
HIV-1 Infections · HIV Infections
Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001
Phase 3 N=1,455 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 — 76.9; 69.5 percentage of responders — p=0.001